Open Nav

Please submit your session questions in advance at

CASI Pharmaceuticals, Inc.

  • George Chi, CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals (NASDAQ: CASI) is a U.S.-based biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world. CASI’s product pipeline features three FDA-approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights currently in various stages in the regulatory process for market approval in China. CASI also acquired a portfolio of 25 FDA-approved ANDAs and four pipeline ANDAs that are pending FDA approval. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China.

  • Date:Monday, February 11
  • Time:10:45 AM - 11:00 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:23251
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Seeking investors, business development
  • Company
  • Company HQ City:Rockville
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Ticker:CASI
  • Exchange:Nasdaq
  • CEO/Top Company Official:Ken K. Ren, PhD
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:ENMD-2076
  • Development Phase of Primary Product:Phase II
George Chi
CASI Pharmaceuticals, Inc.